SB 728 HSPCAlternative Names: SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC
Latest Information Update: 12 Jan 2017
At a glance
- Originator Sangamo BioSciences
- Developer City of Hope National Medical Center; Sangamo Therapeutics; University of Southern California
- Class Cell therapies; Stem cell therapies; Zinc finger DNA binding proteins
- Mechanism of Action CCR5 receptor modulators; Cell replacements; Gene silencing
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I HIV infections